Objectives: To present a rare complication of the use of Cough Lok following coronary artery surgery.
Methods: Case report.
Results: Report of axillary artery thrombosis following use of Cough Lok.
Conclusions: Axillary artery thrombosis as a complication related to the use of the Cough Lok belt has not been previously reported. This rare complication was treated with endovascular thrombolysis. Staff awareness is the most important factor for its prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1569-9293(02)00101-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Late-onset chylothorax after lung cancer surgery: clinical characteristics, management, and prevention.
ANZ J Surg
October 2024
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: The clinical characteristics and management of late-onset chylothorax after lung cancer surgery remained unknown. Here we aimed to provide evidence on the management of late-onset chylothorax by analysis of several cases with the largest sample size.
Methods: We retrospectively collected clinical data of patients who developed late-onset chylothorax after lung cancer surgery and were re-admitted by a single surgeon in our center from 2016 to 2022.
Prevalence and patterns of post-COVID-19 symptoms in recovered patients of Delhi, India: a population-based study.
Osong Public Health Res Perspect
June 2024
National Institute of Health and Family Welfare, New Delhi, India.
Background: Post-coronavirus disease 2019 (COVID-19) symptoms were widely reported. However, data on post-COVID-19 conditions following infection with the Omicron variant remained scarce. This prospective study was conducted to understand the prevalence, patterns, and duration of symptoms in patients who had recovered from COVID-19.
View Article and Find Full Text PDFComparative evaluation of nebulized versus intravenous dexmedetomidine on intubating conditions during awake fiberoptic nasotracheal intubation.
J Clin Anesth
August 2024
Department of Anaesthesiology, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India. Electronic address:
Background: There is a search for an ideal agent to facilitate awake fiberoptic intubation (AFOI). Dexmedetomidine is a selective α2 agonist which can be administered through intravenous, intramuscular, buccal, intranasal & inhalational routes. It provides good intubation conditions without oxygen desaturation but may cause hypotension and bradycardia when administered intravenously.
View Article and Find Full Text PDFEpidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.
Am J Respir Crit Care Med
October 2024
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Cough is a key symptom in patients with fibrotic interstitial lung disease (ILD). This study evaluated the prevalence, longitudinal change, associations, and prognostic significance of cough severity in patients with fibrotic ILD. We included consecutive patients with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrotic ILD who completed the 100-mm Cough Severity Visual Analog Scale from the prospective multicenter Canadian Registry for Pulmonary Fibrosis.
View Article and Find Full Text PDFAntibody Persistence Following Administration of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T and IPV Vaccines and Safety and Immunogenicity of a Booster Dose of DTwP-IPV-HB-PRP~T Administered With an MMR Vaccine in Healthy Infants in India.
Pediatr Infect Dis J
December 2023
Sanofi, Swiftwater, Pennsylvania.
Background: Antibody persistence of a whole-cell pertussis-containing hexavalent vaccine (DTwP-IPV-HB-PRP~T) and its co- or sequential administration with measles, mumps, rubella (MMR) vaccine were evaluated.
Methods: Phase III, open-label, randomized, multicenter study in India. Healthy toddlers 12-24 months of age who had received DTwP-IPV-HB-PRP~T or separate DTwP-HB-PRP~T+IPV primary vaccination at 6-8, 10-12 and 14-16 weeks of age received a DTwP-IPV-HB-PRP~T booster concomitantly with MMR (N = 336) or 28 days before MMR (N = 340).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!